This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Epidemiology

Authoring team

Gaucher disease (GD) is a lysosomal storage disorder (LSD) which is inherited as an autosomal recessive condition with an estimated birth frequency of 1:50,000 to 1:100,000 in the European population with a higher incidence of 1:500 to 1:1000 live births in the Ashkenazi Jewish population

  • the Gauchers Association in the UK report that in 2016 they knew of 310 people with Gaucher disease in the UK and Ireland (293 adults and children in Scotland England and Wales and 17 in all of Ireland)

Type 1

Type 2

Type 3

Phenotype

Accounts for 95% of GD cases.

Diverse phenotypes among patients with identical GBA mutations manifests as variations in the overall severity of the disease, as well as in the pattern of organ involvement

Childhood or adult onset varying from asymptomatic to life threatening symptoms.

Accounts for 1% of GD cases.

Typically neonatal-infantile onset with a rapidly progressive fatal course.

The median age of death is 9 months

Accounts for 4% of GD cases.

Typically infantile-childhood onset; sub-acute and slowly progressive may result in death during the second decade although some have survived to their 4th decade

Reference:

  • Solutions for Public Health, Screening for Gaucher Disease, A report for the UK National Screening Committee. December 2013
  • UK National Screening Committee. Briefing note: Screening for Gaucher disease in newborns. June 2018.

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.